Literature DB >> 29433148

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.

Robert C Gosselin1, Dorothy M Adcock2, Shannon M Bates3, Jonathan Douxfils4, Emmanuel J Favaloro5, Isabelle Gouin-Thibault6, Cecilia Guillermo7, Yohko Kawai8, Edelgard Lindhoff-Last9, Steve Kitchen10.   

Abstract

This guidance document was prepared on behalf of the International Council for Standardization in Haematology (ICSH) for providing haemostasis-related guidance documents for clinical laboratories. This inaugural coagulation ICSH document was developed by an ad hoc committee, comprised of international clinical and laboratory direct acting oral anticoagulant (DOAC) experts. The committee developed consensus recommendations for laboratory measurement of DOACs (dabigatran, rivaroxaban, apixaban and edoxaban), which would be germane for laboratories assessing DOAC anticoagulation. This guidance document addresses all phases of laboratory DOAC measurements, including pre-analytical (e.g. preferred time sample collection, preferred sample type, sample stability), analytical (gold standard method, screening and quantifying methods) and post analytical (e.g. reporting units, quality assurance). The committee addressed the use and limitations of screening tests such as prothrombin time, activated partial thromboplastin time as well as viscoelastic measurements of clotting blood and point of care methods. Additionally, the committee provided recommendations for the proper validation or verification of performance of laboratory assays prior to implementation for clinical use, and external quality assurance to provide continuous assessment of testing and reporting method. Schattauer GmbH Stuttgart.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29433148     DOI: 10.1055/s-0038-1627480

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  56 in total

1.  Should we monitor the direct oral anticoagulants?

Authors:  Robert Diep; David Garcia
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

2.  Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds.

Authors:  Florian Härtig; Sven Poli; Matthias Ebner; Ingvild Birschmann; Joachim Kuhn; Ulf Ziemann; Hans-Ulrich Häring; Rainer Lehmann; Andreas Peter; Sebastian Hörber
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

Review 3.  Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.

Authors:  Alberto Corsini; Nicola Ferri; Marco Proietti; Giuseppe Boriani
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

4.  Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.

Authors:  Ran Nissan; Galia Spectre; Avital Hershkovitz; Hefziba Green; Shai Shimony; Lisa Cooper; Sigal Nakav; Tzippy Shochat; Alon Grossman; Shmuel Fuchs
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

5.  Direct oral anticoagulant monitoring: what laboratory tests are available to guide us?

Authors:  Ravi Sarode
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study.

Authors:  Zhiyan Liu; Qiufen Xie; Qian Xiang; Hanxu Zhang; Guangyan Mu; Zinan Zhao; Taotao Hu; Tingting Wu; Na Wang; Jinhua Zhang; Yan Qian; Shuang Zhou; Zining Wang; Jie Jiang; Yatong Zhang; Hongtao Song; Yimin Cui
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

Review 7.  Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.

Authors:  Michael J Jamieson; Wonkyung Byon; Richard W Dettloff; Matthew Crawford; Peter S Gargalovic; Samira J Merali; Joelle Onorato; Andres J Quintero; Cristina Russ
Journal:  Am J Cardiovasc Drugs       Date:  2022-05-16       Impact factor: 3.571

8.  Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.

Authors:  Markus Gulilat; Denise Keller; Bradley Linton; A Demetri Pananos; Daniel Lizotte; George K Dresser; Jeffrey Alfonsi; Rommel G Tirona; Richard B Kim; Ute I Schwarz
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

9.  Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.

Authors:  Bohyun Kim; Seongsoo Jang; Yu-Jin Lee; Nuree Park; Young-Uk Cho; Chan-Jeoung Park
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 10.  Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation.

Authors:  Gianluca Botto; Pietro Ameri; Manuel Cappellari; Francesco Dentali; Nicola Ferri; Iris Parrini; Italo Porto; Alessandro Squizzato; Giuseppe Camporese
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.